Effects of Dendritic Cell Vaccine Activated with Components of Lieshmania Major on Tumor Specific Response.
CONCLUSION: This study indicates that the use of Leishmania major extract, as well as LPS, can enhance the efficiency of DC-based vaccines and provides a basis for the use of Leishmania major in DC-targeted clinical therapies.
PMID: 31885004 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Fibrosarcoma | HIV-Leishmania Co-infection | Immunotherapy | Iran Health | Middle East Health | Study | Vaccines | Veterinary Vaccinations